Clinical Trial Update: A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating YM155 in combination with Rituximab in patients with previously treated Non-Hodgkin's Lymphoma; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• YM155 (Sepantronium bromide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED